Stockscreener 앱 받기
22.32
2.96%
-0.68
시장 영업 전:
22.44
0.12
+0.54%
전일 마감가:
$23.00
열려 있는:
$23.08
하루 거래량:
888.78K
Relative Volume:
0.67
시가총액:
$2.85B
수익:
$8.40M
순이익/손실:
$-237.42M
주가수익비율:
-11.62
EPS:
-1.9213
순현금흐름:
$-377.03M
1주 성능:
+11.54%
1개월 성능:
-2.40%
6개월 성능:
+95.79%
1년 성능:
+613.10%
1일 변동 폭
$21.98
$23.50
1주일 범위
$19.84
$24.83
52주 변동 폭
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
명칭
Alumis Inc
전화
650-231-6625
주소
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
22.32 | 2.93B | 8.40M | -237.42M | -377.03M | -1.9213 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 개시 | Raymond James | Strong Buy |
| 2026-02-25 | 개시 | Stifel | Buy |
| 2026-01-21 | 개시 | Chardan Capital Markets | Buy |
| 2025-07-25 | 개시 | Wells Fargo | Overweight |
| 2025-06-10 | 재개 | Guggenheim | Buy |
| 2025-01-30 | 개시 | Oppenheimer | Outperform |
| 2024-10-31 | 개시 | Robert W. Baird | Outperform |
| 2024-10-17 | 개시 | H.C. Wainwright | Buy |
| 2024-07-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-07-23 | 개시 | Guggenheim | Buy |
| 2024-07-23 | 개시 | Leerink Partners | Outperform |
| 2024-07-23 | 개시 | Morgan Stanley | Overweight |
모두보기
Alumis Inc 주식(ALMS)의 최신 뉴스
Alumis Stock Sinks As Revenue Shock Jolts Hopes - TipRanks
ALMS Q1 2026 Earnings: EPS Beat Drives 15.55% Stock SurgeRevenue Warning Signal - newsline.com
Alumis Shares Surge 16% as Traders Eye New Drug Move - TechStock²
Why Alumis Inc. Shares Are Suddenly Climbing - TipRanks
ALMS Q1 2026 Earnings: Narrower-Than-Expected Loss Propels Stock HigherMargin Compression Risk - newsline.com
Alumis | SCHEDULE 13D/A: Others - Moomoo
ACT CAPITAL MANAGEMENT, LLC's Alumis Inc(ALMS) Holding History - GuruFocus
ALMS Stock Chart | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Why Alumis Inc. Stock Is Sinking So Sharply - TipRanks
ALMS Q1 2026 Earnings: EPS Surprises to the Upside Amid Pre-Revenue Clinical StagePre-Earnings Drift - newsline.com
Has Alumis's Envudeucitinib Redefined Psoriasis Treatment - Kavout
Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements - Insider Monkey
Alumis Inc. (ALMS) Edges Higher: Modest Gains Amid Key Support and Resistance LevelsHedge Fund Exposure - newsline.com
ALMS Q1 2026 Earnings: EPS Beat Partially Offsets Investor ConcernsProfit Cycle Analysis - The Legal Advocate
Alumis (ALMS) Chief Medical Officer exercises stock options for 26,852 shares - Stock Titan
10 Under-the-Radar Stocks with Massive Upside for 2026 - Insider Monkey
TOWERVIEW LLC's Alumis Inc(ALMS) Holding History - GuruFocus
Alumis Inc. promotes investigational TYK2 inhibitor envudeucitinib at clinical dermatology congress - Traders Union
Alumis Inc. (ALMS) Q1 2026 Earnings: Narrower Loss Mirrors Operational Discipline, Pre-Revenue Stage PersistsEPS Guidance Update - The Legal Advocate
Alumis Inc. (ALMS) Edges Lower, Consolidating Above Key Support LevelWyckoff Distribution - newsline.com
How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors - simplywall.st
Alumis | S-3ASR: Automatic shelf registration statement of securities of well-known seasoned issuers - Moomoo
Alumis Analyst Ratings and Price Targets | NASDAQ:ALMS - Benzinga
Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model? - Yahoo Finance
ALMS Maintained by Chardan Capital -- Price Target Raised to $40 - GuruFocus
Chardan Capital Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Alumis price target raised to $40 from $38 at Chardan - TipRanks
Chardan Raises Price Target on Alumis to $40 From $38, Keeps Buy Rating - marketscreener.com
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Data And Upcoming Regulatory Milestones - Sahm
This Alumis analyst is no longer bullish; here are top 5 downgrades for Friday - MSN
ALUMIS INC. ($ALMS) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] ALUMIS INC. SEC Filing - Stock Titan
[DEF 14A] ALUMIS INC. Definitive Proxy Statement - Stock Titan
Cormorant Asset Management Acquires 313,645 Shares of Alumis in Q1 2026 - IndexBox
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - The Motley Fool
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter - The Motley Fool
Should Alumis’ (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors? - Sahm
Alumis’ Envudeucitinib Hits 68% PASI 90 in Phase 3 Psoriasis Trial - The Clinical Trial Vanguard
HC Wainwright & Co. downgrades Alumis (ALMS) - MSN
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back - AOL.com
A Quick Look at Today's Ratings for Alumis(ALMS.US), With a Forecast Between $25 to $55 - Moomoo
All News about Alumis Inc.Common Stock - The Chronicle-Journal
ALMS Maintained by Guggenheim -- Price Target Raised to $34 - GuruFocus
ALMS Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
Aardvark’s next move after clinical hold; Alumis’ verdict on Acelyrin asset - Endpoints News
Stifel reiterates Alumis stock rating on psoriasis trial data By Investing.com - Investing.com South Africa
Stifel reiterates Alumis stock rating on psoriasis trial data - Investing.com
Why Alumis Inc. Stock Is Sliding After Good News - TipRanks
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
H.C. Wainwright Downgrades Alumis(ALMS.US) to Hold Rating, Maintains Target Price $25 - Moomoo
Wells Fargo Maintains Alumis(ALMS.US) With Buy Rating, Raises Target Price to $51 - Moomoo
Alumis Inc (ALMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alumis Inc 주식 (ALMS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director |
Jan 09 '26 |
Buy |
17.00 |
588,235 |
9,999,995 |
1,853,488 |
| Foresite Labs, LLC | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Foresite Capital Management VI | 10% Owner |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| Tananbaum James B. | Director |
Jan 08 '26 |
Buy |
17.00 |
411,764 |
6,999,988 |
5,702,536 |
| AKKARAJU SRINIVAS | Director |
Dec 05 '25 |
Buy |
9.84 |
186,377 |
1,833,760 |
1,265,253 |
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
1.27%
1.43%
자본화:
|
볼륨(24시간):